Full Breakdown
Ebola Outbreak in the Democratic Republic of Congo Accelerates as Cases Surge Past 5,700
8/29/2026, 8:54:22 PM
Rapid Expansion to New Health Zones
Government data released on August 29, 2026 show the epidemic has reached two additional health zones—Biena and Manguredjipa—in North Kivu, bringing the total number of affected zones to 60. In the newly affected zones the case-fatality rate is markedly higher than the national average of 48 percent, reflecting delayed response and limited health-care access.
Scale of the Outbreak
- Confirmed cases: 5,794 (WHO) and 5,713 (DRC Ministry of Health).
- Deaths: 2,786 (WHO) and 2,744 (ministry).
- Overall fatality rate: ? 48 percent; in Beni (North Kivu) ? 69 percent.
- Comparison: WHO warns the outbreak could exceed the 2014-2016 West-Africa epidemic that killed > 11,000 people.
The differing tallies illustrate a reporting gap between WHO’s August 14, 2026 situation report and the Congolese government’s daily updates.
Challenges Hindering Response
The spread occurs amid armed conflict, massive displacement, a health-workers’ strike, and frequent cross-border movement. Treatment-center capacity is strained; the Nizi centre in Ituri was operating at 278 percent of its designed capacity on August 2, 2026. Health-worker infections total 151 by July 30, 2026 (44 deaths), rising to 160 by early August.
Vaccination Effort and Clinical Trial
On Thursday the vaccination campaign launched in Kisangani, targeting frontline staff. The Ministry of Health has secured 70,000 doses of the Ervebo vaccine, with 50,000 for health workers and 20,000 for a clinical trial assessing cross-protection against the Bundibugyo strain. WHO notes Ervebo is licensed for Zaire ebolavirus and its efficacy against Bundibugyo remains unproven.
International and Organizational Responses
- WHO continues to list the outbreak as a public-health emergency of international concern, citing a “substantial increase” in geographic spread.
- Médecins Sans Frontières (MSF) opened a new treatment centre in Beni, describing it as essential for rapid care, contact tracing, and containment.
Conflicting Reports & Gaps
- Case counts: WHO’s 5,794 cases differ from the ministry’s 5,713 cases.
- Vaccine efficacy: No peer-reviewed data confirm Ervebo’s protection against Bundibugyo; WHO labels the benefit as “not known.”
- Cross-border risk: WHO flags the Central African Republic and South Sudan as high-risk for spillover, but surveillance data remain limited.
What’s Next
The vaccination programme aims to cover 14 health zones across Tshopo, Bas-Uele and Haut-Uele provinces. Ongoing clinical trials will evaluate Ervebo’s cross-protective effect, while WHO and partner agencies continue to monitor border movements and support contact-tracing operations.
Verbatim Quotes
- “We have decided to use the Ervebo vaccine to protect first those who are on the front line, therefore our health care providers, but also people who have been in contact with patients,” — Roger Kamba, health minister
- “While vaccines are an important and valuable tool to help in these types of outbreaks, the core principles of tracing contacts of the confirmed cases and isolating them is what will ultimately stop the chains of transmission. This is underway and improving, but resources are needed to make sure that these efforts catch up to the pace of the outbreak,” — Dr. Titanji
- “The outbreak is growing faster and wider than the Ebola response,” — Julien Harneis
